Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
In nuclear medicine, the transition from statistical and population-based care to individual and personalized medicine enables numerous enhancements to the standard-of-care in cancer therapy. In this context, an expanding lineup of radionuclides with various decay properties and chemistry allows for precise alignment of these aspects with the biology and pharmacokinetics of molecular targeting agents. Indeed, the application of radionuclide-based therapeutics and companion imaging agents have seen dramatic improvements in recent decades – considerable advances have been made at every stage of radiopharmaceutical development which has provided improved isotope availability, in vivo stability, target specificity, and reduced toxicity. Especially with regard to radiotherapeutic agents, progress in these areas has been largely dominated by the radiometals. The anti-cancer function of radiotherapeutic pharmaceuticals is mechanistically different from those used in chemotherapeutic intervention. The first portion of this chapter aims to provide an abbreviated but adequate discussion of the various types of therapeutically relevant decay modes and the dominant radiobiological effects of their corresponding radiations. The remaining portion of this chapter investigates specific radionuclides, how their unique properties are leveraged within clinically and preclinically promising therapeutic strategies, and also addresses critical barriers to implementation of each nuclide in research or clinical practice.
In nuclear medicine, the transition from statistical and population-based care to individual and personalized medicine enables numerous enhancements to the standard-of-care in cancer therapy. In this context, an expanding lineup of radionuclides with various decay properties and chemistry allows for precise alignment of these aspects with the biology and pharmacokinetics of molecular targeting agents. Indeed, the application of radionuclide-based therapeutics and companion imaging agents have seen dramatic improvements in recent decades – considerable advances have been made at every stage of radiopharmaceutical development which has provided improved isotope availability, in vivo stability, target specificity, and reduced toxicity. Especially with regard to radiotherapeutic agents, progress in these areas has been largely dominated by the radiometals. The anti-cancer function of radiotherapeutic pharmaceuticals is mechanistically different from those used in chemotherapeutic intervention. The first portion of this chapter aims to provide an abbreviated but adequate discussion of the various types of therapeutically relevant decay modes and the dominant radiobiological effects of their corresponding radiations. The remaining portion of this chapter investigates specific radionuclides, how their unique properties are leveraged within clinically and preclinically promising therapeutic strategies, and also addresses critical barriers to implementation of each nuclide in research or clinical practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.